The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of ...
The Pancreatic Cancer Action Network responds to FDA approval of Rasonque™ (daraxonrasib) for patients with previously ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit discusses what she learned at the inaugural AACR Drug Discovery ...
The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement today following the full data from Revolution ...
I can’t think of a more exciting and hopeful time for pancreatic cancer than now. We are finally beginning to reap the benefits of decades of research into this challenging cancer. Because KRAS ...
Today, the President’s budget request (PBR) was released, and while the PBR is just that – a request – it signals the administration’s priorities for the coming fiscal year 2027, and once again, it ...
The U.S. Food and Drug Administration (FDA) has approved a wearable medical device used in combination with a standard chemotherapy regimen for the treatment of adult patients with locally advanced ...
I’ve been advocating for patients with pancreatic cancer for 27 years. Never have I seen a year with so much uncertainty and turmoil in federal cancer research funding. But despite the instability and ...
LOS ANGELES, Calif. – (January 13, 2026) – Pancreatic cancer remains the third-leading cause of cancer-related deaths in the United States, behind lung and colorectal cancers. According to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results